HF 17 (see companion bill SF 168) – Minnesota

Status: In Process
Year Introduced: 2023
Link: https://www.revisor.mn.gov/bills/bill.php?b=House&f=HF0017&ssn=0&y=2023

This bill prohibits a manufacturer from imposing or causing to be imposed an excessive price increase on the sale of any generic or off-patent drug. The bill requires the commissioner of health to notify the manufacturer, attorney general, and Board of Pharmacy of any violation of the prohibition on excessive price increases. The bill requires manufacturers that receive a notice to provide specified information on drug costs to the attorney general, and allows the attorney general to investigate a possible violation and petition the court to issue orders for various remedies. The bill also prohibits a manufacturer from withdrawing a drug from sale in the state in order to avoid the prohibition on excessive price increases. The bill makes a violation by a manufacturer of the prohibition on excessive price increases, and related requirements, grounds for disciplinary action by the Board of Pharmacy. (See §§ 1-6, 18, 19.) This bill also establishes the Prescription Drug Affordability Board and a related advisory council to review the cost of prescription drugs and set upper payment limits for drugs whose cost creates an affordability challenge to the state health care system or patients. The bill requires the board to identify drug products whose introductory prices and price increases meet specified criteria, and allows the board to conduct drug cost reviews. If the board determines that spending on a drug product creates an affordability challenge, the board is directed to set upper payment limits for purchases of, and reimbursement for, the drug. Failures of entities to comply with these reimbursement levels, and failures of drug manufacturers to comply with reporting requirements, are subject to action by the attorney general. (See §§ 7-17, 20.)

Return to Database Search

© 2018- The SLIHCQ DatabaseInitial funding for this project was provided by the Robert Wood Johnson Foundation. The views expressed here do not necessarily reflect the views of the Foundation.

Associated Litigation:

No items found